Euro
USD
British Pound
NULL
Product Description
Dynactin 2 (L371) polyclonal Antibody | BS1271 | Bioworld
Host: Rabbit
Reactivity: Human,Mouse,Rat
Application: IHC
Application Range: IHC: 1:50~1:200
Background: Dynactin is a multisubunit complex that functions as a binding partner for the Dynein microtubule motor. Dynactin-Dynein binding may be required for most, if not all, cytoplasmic Dynein-driven activities and is thought to contribute to the functional diversity of Dynein. Dynactin 2, also known as DCTN2, Dynamitin or DCTN50, is a peripheral membrane protein that is one of many subunits in the Dynactin complex. Like other Dynactin subunits, Dynactin 2 mediates Dynein-organelle binding and helps to regulate chromosome alignment during prometaphase and spindle organization during mitosis. Overexpression of Dynactin 2 disrupts the Dynactin-Dynein complex, thus inhibiting retrograde axonal transport and causing motor neuron degeneration. Additionally, overexpression of Dynactin 2 may disrupt the cell cycle and lead to osteosarcoma, suggesting a possible role for Dynactin 2 in carcinogenesis
Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity: Dynactin 2 (L371) polyclonal Antibody detects endogenous levels of pDynactin 2 protein.
Molecular Weight: ~ 44 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: Dynactin subunit 2; 50 kDa dynein-associated polypeptide; Dynactin complex 50 kDa subunit; DCTN-50; p50 dynamitin; DCTN2; DCTN50
Immunogen: Synthetic peptide, corresponding to amino acids 340-390 of Human Dynactin 2.
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Pathway: Regulation of Apoptosis,Hypoxia Signaling,Warburg Effect,Signaling Pathways Activating p38 MAP KinaseCell Cycle Control G1 S Checkpoint,Examples of Crosstalk Between Post-translational Modifications,Cell Cycle G2 M DNA Damage Signaling Pathway,
